Please login to your online account to display your discounted pricing

Phospho-ATM (S1981) Mouse, Clone: 10H11.E12, eBioscience™

Mouse Monoclonal Antibody

$143.55 - $361.05

Specifications

Antigen Phospho-ATM (S1981)
Clone 10H11.E12
Host Species Mouse
Gene Alias Ataxia-telangiectasia mutated
Species Reactivity Human, Mouse, Rat
View More Specs

 Disclaimers

For Research Use Only.

Products
Catalog Number Mfr. No. Quantity Price Quantity    

501122752

 
affymetrix
14904682
100μg Each for $361.05

501122751

 
affymetrix
14904680
25μg Each for $143.55
Description & Specifications

Specifications

Antigen Phospho-ATM (S1981)
Clone 10H11.E12
Host Species Mouse
Gene Alias Ataxia-telangiectasia mutated
Species Reactivity Human, Mouse, Rat
Applications Flow Cytometry (Intracellular Staining)
Applications Immunocytochemistry
Applications Immunohistochemistry (Formalin/Paraffin)
Applications Immunoprecipitation
Applications Western Blotting
Regulatory Status RUO
Conjugate Unlabeled
Format Purified
Storage Requirements Store at 2-8°C.
Primary or Secondary Primary
Monoclonal or Polyclonal Monoclonal
Formulation aqueous buffer, 0.09% sodium azide, may contain carrier protein/stabilizer
Concentration 0.5mg/mL

This 10H11.E12 monoclonal antibody recognizes the human, mouse, and rat ataxia-telangiectasia (ATM) protein when phosphorylated on serine 1981. ATM belongs to the family of PI3 kinases and functions by coordinating cell cycle arrest and initiation of DNA repair through the phosphorylation of a multitude of substrates in response to DNA damage and oxidative stress. ATM exists as dimers or multimers in its inactive state but in response to DNA breaks, becomes activated through formation of monomers and autophosphorylation. Activated ATM is recruited to the site of DNA double strand breaks where it halts the cell cycle and initiates DNA repair through the phosphorylation of downstream DNA damage response pathway members. Loss of functional activity of ATM results in ataxia-telangiectasia (AT), a disease characterized by early onset neurodegeneration and predisposition to cancer. AT patients are immunodeficient, radiosensitive, and have an increased risk of certain cancer types such as lymphoma and leukemia.